Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Naftifine Hydrochloride 2% Cream in Tinea Pedis
NCT02633813Phase 3Completed
- Sponsor
- Genzum Life Sciences
- Start
- Mar 2015
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of naftifine organogel (MediQuest Therapeutics) in tinea pedis (3 arms), sponsored by Genzum Life Sciences. Primary endpoint: Mycological cure and clinical cure for a single target lesion for Trichyphyton rubrum at 6 weeks. Started Mar 2015; status: completed.
02
Drugs
naftifine organogel (MediQuest Therapeutics)
03
Conditions
tinea pedis
Beyond the preview
Go deeper on NCT02633813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02633813.